Rchr
J-GLOBAL ID:201901011686661781   Update date: Feb. 08, 2024

Jun Ishizaki

イシザキ ジュン | Jun Ishizaki
Affiliation and department:
Job title: 講師(病院教員)
Research field  (1): Allergies and connective tissue disease
Research keywords  (4): リウマチ・膠原病 ,  血管炎症候群 ,  バイオマーカー ,  プロテオミクス
Research theme for competitive and other funds  (3):
  • 2023 - 2026 難治性血管炎の新たな寛解維持・腎予後予測マーカーおよび分子標的治療の臨床応用
  • 2020 - 2023 Verification of novel biomarkers of disease activity in vasculitis syndrome for practical use and identification of novel therapeutic targets
  • 2017 - 2020 Identification and analysis of biomarkers of disease activity and organ involvement in antineutrophil cytoplasmic antibody-associated vasculitis by quantitative proteomics
Papers (24):
  • Jun Ishizaki, Hitoshi Hasegawa. Design an Intervention Study. Methods in molecular biology (Clifton, N.J.). 2024. 2766. 317-324
  • Jun Ishizaki, Hitoshi Hasegawa. Assessment of Disease Activity, Structural Damage, and Function in Rheumatoid Arthritis. Methods in molecular biology (Clifton, N.J.). 2024. 2766. 325-333
  • Jun Ishizaki. Assessment of Musculoskeletal Ultrasound of Rheumatoid Arthritis. Methods in molecular biology (Clifton, N.J.). 2024. 2766. 335-342
  • Takahiko Sugihara, Hajime Yoshifuji, Haruhito A Uchida, Yasuhiro Maejima, Yoshiko Watanabe, Kazuo Tanemoto, Natsuka Umezawa, Yusuke Manabe, Jun Ishizaki, Tsuyoshi Shirai, et al. Establishing clinical remission criteria for giant cell arteritis: Results of a Delphi exercise carried out by an expert panel of the Japan Research Committee of the Ministry of Health, Labour, and Welfare for Intractable Vasculitis. Modern rheumatology. 2023
  • Takahiko Sugihara, Haruhito A Uchida, Hajime Yoshifuji, Yasuhiro Maejima, Taio Naniwa, Yasuhiro Katsumata, Takahiro Okazaki, Jun Ishizaki, Yohko Murakawa, Noriyoshi Ogawa, et al. Association between the patterns of large-vessel lesions and treatment outcomes in patients with large-vessel giant cell arteritis. Modern rheumatology. 2022
more...
MISC (37):
  • 石崎 淳. 【血管炎の診断update-診断・治療の新展開-】最近のトピックス ANCA関連血管炎のバイオマーカー. 日本臨床. 2022. 80. 8. 1320-1325
  • 長谷川 均, 石崎 淳, 武森 信曉. 【血管炎の診断と治療:エッセンスと今後の展望】各種血管炎の診断・鑑別診断と治療 免疫複合体性小型血管炎. 診断と治療. 2021. 109. 10. 1415-1420
  • 長谷川均, 石崎 淳. 【血管炎症候群のすべて】巨細胞性動脈炎(側頭動脈炎) 疫学・病態・症状・診断基準. 臨床放射線. 2021. 66. 10. 1045-1052
  • 長谷川 均, 石崎 淳, 武森 信曉. 【ANCA関連血管炎の病因研究】ANCA関連血管炎におけるプロテオーム解析. 炎症と免疫. 2020. 28. 4. 273-278
  • 石崎 淳, 長谷川 均. 【リウマチ性疾患の診断・疾患活動性評価のバイオマーカー】血管炎症候群. リウマチ科. 2020. 63. 1. 28-36
more...
Books (1):
  • リウマチ病学テキスト
    南江堂 2022 ISBN:9784524231584
Lectures and oral presentations  (2):
  • Useful biomarkers in the management of vasculitides
    (The 66th Annual General Assembly and Scientific Meeting of the JCR, Symposium 5 Rapidly changing paradigm of vasculitis treatment 2022)
  • Novel biomarkers of disease activity in ANCA-associated vasculitis
    (23rd Asia-Pacific League of Associations for Rheumatology Congress 2021)
Education (2):
  • 2012 - 2016 Ehime University Graduate School of Medicine
  • 2000 - 2006 Ehime University School of Medicine Faculty of Medicine
Professional career (1):
  • 博士課程 (愛媛大学大学院医学系研究科)
Work history (5):
  • 2016/08 - 現在 Ehime University Graduate School of Medicine, Japan Department of Hematology, Clinical Immunology and Infectious Diseases Designated Lecturer
  • 2016/04 - 2016/07 Ehime University Graduate School of Medicine, Japan Department of Hematology, Clinical Immunology and Infectious Diseases Assistant professor
  • 2012/04 - 2016/03 Ehime University Graduate School of Medicine, Japan Department of Hematology, Clinical Immunology and Infectious Diseases
  • 2011/07 - 2012/03 University of Occupational and Environmental Health, Japan First Department of Internal Medicine Assistant professor
  • 2011/04 - 2011/06 University of Occupational and Environmental Health, Japan First Department of Internal Medicine
Committee career (1):
  • 2021/12 - 日本リウマチ学会中国・四国支部 評議員
Association Membership(s) (3):
日本臨床免疫学会 ,  日本内科学会 ,  日本リウマチ学会
※ Researcher’s information displayed in J-GLOBAL is based on the information registered in researchmap. For details, see here.

Return to Previous Page